Cargando…

Diagnostic Role of Prostate-Specific Membrane Antigen in Adrenocortical Carcinoma

Objective: To investigate the role of PSMA in the differential diagnosis of adrenocortical carcinoma samples (ACCs) and adrenocortical adenoma samples (ACAs), to validate the prognostic role of PSMA in patients with ACCs, and to explore the possibility that this marker can differentiate localized AC...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Yulin, Gu, Weijun, Dou, Jingtao, Lu, Zhaohui, Ba, Jianming, Li, Jie, Wang, Xiaocong, Liu, Hongyan, Yang, Guoqing, Guo, Qinghua, Zang, Li, Chen, Kang, Du, Jin, Pei, Yu, Mu, Yiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6476981/
https://www.ncbi.nlm.nih.gov/pubmed/31040822
http://dx.doi.org/10.3389/fendo.2019.00226
_version_ 1783412973717422080
author Gu, Yulin
Gu, Weijun
Dou, Jingtao
Lu, Zhaohui
Ba, Jianming
Li, Jie
Wang, Xiaocong
Liu, Hongyan
Yang, Guoqing
Guo, Qinghua
Zang, Li
Chen, Kang
Du, Jin
Pei, Yu
Mu, Yiming
author_facet Gu, Yulin
Gu, Weijun
Dou, Jingtao
Lu, Zhaohui
Ba, Jianming
Li, Jie
Wang, Xiaocong
Liu, Hongyan
Yang, Guoqing
Guo, Qinghua
Zang, Li
Chen, Kang
Du, Jin
Pei, Yu
Mu, Yiming
author_sort Gu, Yulin
collection PubMed
description Objective: To investigate the role of PSMA in the differential diagnosis of adrenocortical carcinoma samples (ACCs) and adrenocortical adenoma samples (ACAs), to validate the prognostic role of PSMA in patients with ACCs, and to explore the possibility that this marker can differentiate localized ACCs from adrenal metastases from other sites. Methods: PSMA protein expression in tissue samples from 50 ACCs, 90 ACAs (including 20 from patients who presented with Cushing's syndrome, 20 aldosterone-producing adenomas and 50 non-functional tumors) and 10 tissues that were metastases from other primary sites was assessed by immunohistochemistry. The clinical and pathological characteristics were compared, the intensity and density were analyzed, and the prognostic role was evaluated. Results: The analysis of clinical and pathological features revealed that the size of ACCs was greater than that of benign tissues and the ACC patients were older than the ACA patients (p < 0.01). The percentage of PSMA-positive vessels, the mean intensity and the degree of staining density were found to be significantly lower in ACAs than in ACCs (p < 0.01). In these 140 samples, 60% of the ACCs were grouped in the positive category. The samples were negative for metastases that were from other primary sites. The ENSAT stage and Ki-67 were correlated with PSMA expression. The survival distribution revealed that high PSMA expression did not show any prognostic relevance in the current ACCs series. Those samples with a score of > 3.5 were 75 times more likely to be malignant (OR = 75). We established a cut-off score of 3.5 (p < 0.05), which had 46% sensitivity and 99% specificity. Paralleling PSMA and Ki-67 maximized the area under the curve, with 72% sensitivity and 100% specificity. Conclusions: Our results strongly confirm that PSMA is helpful for distinguishing benign from malignant tumors and that its high expression levels correlate with a high ENSAT stage and high proliferation. The combination of PSMA and Ki-67 can be particularly useful. Furthermore, PSMA might be a useful tool for the identification of localized adrenal carcinoma and metastatic carcinoma.
format Online
Article
Text
id pubmed-6476981
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64769812019-04-30 Diagnostic Role of Prostate-Specific Membrane Antigen in Adrenocortical Carcinoma Gu, Yulin Gu, Weijun Dou, Jingtao Lu, Zhaohui Ba, Jianming Li, Jie Wang, Xiaocong Liu, Hongyan Yang, Guoqing Guo, Qinghua Zang, Li Chen, Kang Du, Jin Pei, Yu Mu, Yiming Front Endocrinol (Lausanne) Endocrinology Objective: To investigate the role of PSMA in the differential diagnosis of adrenocortical carcinoma samples (ACCs) and adrenocortical adenoma samples (ACAs), to validate the prognostic role of PSMA in patients with ACCs, and to explore the possibility that this marker can differentiate localized ACCs from adrenal metastases from other sites. Methods: PSMA protein expression in tissue samples from 50 ACCs, 90 ACAs (including 20 from patients who presented with Cushing's syndrome, 20 aldosterone-producing adenomas and 50 non-functional tumors) and 10 tissues that were metastases from other primary sites was assessed by immunohistochemistry. The clinical and pathological characteristics were compared, the intensity and density were analyzed, and the prognostic role was evaluated. Results: The analysis of clinical and pathological features revealed that the size of ACCs was greater than that of benign tissues and the ACC patients were older than the ACA patients (p < 0.01). The percentage of PSMA-positive vessels, the mean intensity and the degree of staining density were found to be significantly lower in ACAs than in ACCs (p < 0.01). In these 140 samples, 60% of the ACCs were grouped in the positive category. The samples were negative for metastases that were from other primary sites. The ENSAT stage and Ki-67 were correlated with PSMA expression. The survival distribution revealed that high PSMA expression did not show any prognostic relevance in the current ACCs series. Those samples with a score of > 3.5 were 75 times more likely to be malignant (OR = 75). We established a cut-off score of 3.5 (p < 0.05), which had 46% sensitivity and 99% specificity. Paralleling PSMA and Ki-67 maximized the area under the curve, with 72% sensitivity and 100% specificity. Conclusions: Our results strongly confirm that PSMA is helpful for distinguishing benign from malignant tumors and that its high expression levels correlate with a high ENSAT stage and high proliferation. The combination of PSMA and Ki-67 can be particularly useful. Furthermore, PSMA might be a useful tool for the identification of localized adrenal carcinoma and metastatic carcinoma. Frontiers Media S.A. 2019-04-16 /pmc/articles/PMC6476981/ /pubmed/31040822 http://dx.doi.org/10.3389/fendo.2019.00226 Text en Copyright © 2019 Gu, Gu, Dou, Lu, Ba, Li, Wang, Liu, Yang, Guo, Zang, Chen, Du, Pei and Mu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Gu, Yulin
Gu, Weijun
Dou, Jingtao
Lu, Zhaohui
Ba, Jianming
Li, Jie
Wang, Xiaocong
Liu, Hongyan
Yang, Guoqing
Guo, Qinghua
Zang, Li
Chen, Kang
Du, Jin
Pei, Yu
Mu, Yiming
Diagnostic Role of Prostate-Specific Membrane Antigen in Adrenocortical Carcinoma
title Diagnostic Role of Prostate-Specific Membrane Antigen in Adrenocortical Carcinoma
title_full Diagnostic Role of Prostate-Specific Membrane Antigen in Adrenocortical Carcinoma
title_fullStr Diagnostic Role of Prostate-Specific Membrane Antigen in Adrenocortical Carcinoma
title_full_unstemmed Diagnostic Role of Prostate-Specific Membrane Antigen in Adrenocortical Carcinoma
title_short Diagnostic Role of Prostate-Specific Membrane Antigen in Adrenocortical Carcinoma
title_sort diagnostic role of prostate-specific membrane antigen in adrenocortical carcinoma
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6476981/
https://www.ncbi.nlm.nih.gov/pubmed/31040822
http://dx.doi.org/10.3389/fendo.2019.00226
work_keys_str_mv AT guyulin diagnosticroleofprostatespecificmembraneantigeninadrenocorticalcarcinoma
AT guweijun diagnosticroleofprostatespecificmembraneantigeninadrenocorticalcarcinoma
AT doujingtao diagnosticroleofprostatespecificmembraneantigeninadrenocorticalcarcinoma
AT luzhaohui diagnosticroleofprostatespecificmembraneantigeninadrenocorticalcarcinoma
AT bajianming diagnosticroleofprostatespecificmembraneantigeninadrenocorticalcarcinoma
AT lijie diagnosticroleofprostatespecificmembraneantigeninadrenocorticalcarcinoma
AT wangxiaocong diagnosticroleofprostatespecificmembraneantigeninadrenocorticalcarcinoma
AT liuhongyan diagnosticroleofprostatespecificmembraneantigeninadrenocorticalcarcinoma
AT yangguoqing diagnosticroleofprostatespecificmembraneantigeninadrenocorticalcarcinoma
AT guoqinghua diagnosticroleofprostatespecificmembraneantigeninadrenocorticalcarcinoma
AT zangli diagnosticroleofprostatespecificmembraneantigeninadrenocorticalcarcinoma
AT chenkang diagnosticroleofprostatespecificmembraneantigeninadrenocorticalcarcinoma
AT dujin diagnosticroleofprostatespecificmembraneantigeninadrenocorticalcarcinoma
AT peiyu diagnosticroleofprostatespecificmembraneantigeninadrenocorticalcarcinoma
AT muyiming diagnosticroleofprostatespecificmembraneantigeninadrenocorticalcarcinoma